Verge Turns Failed ALS Trial Into AI Model
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Verge Genomics, co-founded more than a decade ago by Alice Zhang, built its platform around mapping gene networks underlying neurodegenerative diseases including Parkinson's, ALS, and Alzheimer's.
- Verge's ALS drug candidate failed its Phase 1b trial last month, with one-third of enrolled patients dropping out because they could not tolerate the drug.
- The company's earlier target-discovery work produced two targets that Eli Lilly nominated to its internal pipeline in 2024.
- Verge published a public postmortem of the failed trial, with Zhang arguing that sharing negative results benefits 'not just for us, but for the field and for ALS broadly' — a practice she noted is 'not done very often.'
- Verge Labs repurposed the failed trial's patient data into a new AI benchmarking model designed to address patient stratification problems in neurology clinical trials.
Why it matters: By converting a failed Phase 1b ALS trial — where one-third of patients dropped out due to drug intolerance — into a shared AI benchmarking dataset, Verge is modeling the kind of trial-failure transparency Zhang says is 'not done very often.' The move gives neurology drug developers a new patient-stratification tool and puts a rare public spotlight on what sponsors usually bury after a setback.
